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Background
Due to their clinical importance, the development of
therapeutic proteins has accelerated immensely over the
past years. However, the expression of highly glycosy-
lated recombinant therapeutic proteins, as for example
blood coagulation factors or serum proteins has
remained a challenging task. Human cell lines, as
HEK293 cells or our amniocyte-derived CAP cell line,
appear to be efficient in producing and secreting these
proteins, however glycosylation can be incomplete.
Although, we have found that CAP cells generate a
more authentic human glycosylation pattern than
HEK293, we have for some proteins, e.g. human C1
esterase inhibitor (hC1-Inh), also detected incomplete
sialylation, resulting in reduced serum half-life of the
recombinant protein.
C1 esterase Inhibitor (C1 Inh) belongs to the serpin
superfamily. Its main function is the inhibition of the
complement system to prevent spontaneous activation.
The 500 aa protein is highly glycosylated with 7 predicted
N-glycans and 8 predicted O-linked glycans. Plasma
derived C1 Inhibitors (Berinert, CSL Behring and Cin-
ryze, ViroPharma,) as well as recombinant C1 Inh derived
from milk of transgenic rabbits (Ruconest, Pharming N.
V.) are approved for the treatment of acute attacks in
patients with hereditary angioedema (HAE). However,
the recombinant product shows a dramatically reduced
serum half-life in pharmacokinetic studies in comparison
to the plasma derived counterparts.
Results
We have further developed the CAP cell line (CAP-Go
cells) to confer optimal glycosylation to highly complex
glycoproteins like C1 Inh. Among these, the CAP-Go.1
cell line has been modified to facilitate expression of
proteins with fully sialylated N-linked glycans. Recombi-
nant proteins like human alpha-antitrypsin or human
placental alkaline phosphatase produced with CAP-Go.1
show a significantly prolonged serum half-life in rats
(data not shown). However, when human C1 Inh is
expressed in CAP-Go.1 cells, this has no positive impact
on the pharmacokinetic profile (Figure 1, D+E). Additional
modifications of the CAP cell line have resulted in the
CAP-Go.2 cell line, which addresses the O-linked glycosy-
lation patterns.
Expression of recombinant human rhC1Inh in CAP-
Go.2 cells results in a significantly increased serum
half-life of the produced protein compared to its coun-
terpart generated on a conventional expression plat-
form and is actually indistinguishable from to the
plasma-purified protein (Figure 1, D+E). While rhC1
Inh proteins expressed in either CAP-Go.1 or CAP-
Go.2 cells both show a similar reduction of free term-
inal galactose on N-linked glycans (Figure 1, B), their
O-glycans differ. Analysis of the O-Glycans shows that
rhC1 Inh expressed by CAP-Go.2 cells, but not CAP-
Go.1, contains only core1 O-linked glycan structures,
highly comparable to plasma-derived Berinert. Overall,
glycans of recombinant C1 Inh expressed in CAP-Go.2
cells are more homogenous than the glycans found on
conventional recombinant glycoproteins, resulting in
lower batch to batch variations and reduced down-
stream cost due to high expression of recombinant
proteins with the desired glycoprofile.
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Conclusions
In this work, we present our approach for the expression
of recombinant glycoproteins, like human C1 Inhibitor
(rhC1 Inh) with excellent pharmacokinetik properties
using modified CAP cells. Our results indicate that in
addition to N-glycosylation, also the structure of O-linked
glycans plays a crucial role in bioavailability and pharma-
cokinetic properties of glycoproteins. rhC1 Inh expressed
from CAP-Go.2 cells that have been optimized for the
expression of N- and O-glycosylated proteins display gly-
can patterns closely similar to plasma-derived C1 Inh and
the resulting molecule has a significantly prolonged serum
half-life as compared to its counterpart generated on a
conventional human cell line. Our new recombinant mole-
cule matches serum-derived C1 in all aspects analyzed:
specific activity, serum half-life, and glycosylation pattern
(Figure 1 and data not shown) and offers the advantage of
being producible at large scale on a safe platform.
Glycans found on non-antibody biopharmaceuticals
can be highly complex involving antennary fucose, Lac-
di-Nac structures and a variable number of antennae,
just on N-linked glycans. To address these challenges
we have developed additional CAP-Go cell lines that
can be employed to generate recombinant proteins with
tailor made glycan structures.
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Figure 1 Expression of recombinant human C1 Inh in CAP-Go.2 cells results in glycoproteins with increased sialylation of N-glycans,
homogenous core 1 O-glycosylation and significant increased serum half-life. A) Recombinant proteins were produced using the indicated
platform, purified and subjected to isolelectric focusing (IEF) gel analysis in comparison to plasma-derived Berinert. B) ECL Lectin Blot, comparing
degree of sialylation between different CAP-Go cell lines and hC1 Inh from human serum (Berinert). Erythrina cristagalli lectin binds to terminal
galactose on N-glycans, sialic acid prevents the lectin from binding, therefore decrease signal intensity indicates increase in sialylation. C) MALDI-
TOF mass spectrum analysis of C1 Inh O-glycans of protein expressed in CAP-Go.1 or CAP-Go.2 cell lines in comparison to Berinert. D and E) C1
Inh preparations were injected intravenously at 10 mg/kg into female Sprague Dawley rats. Residual C1 in plasma samples taken at the indicated
time points was analyzed by ELISA.
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